All relevant data are within the paper and its Supporting Information files. Additional data are accessible in case of need in the Agamenon registry.

Introduction {#sec005}
============

Advanced gastric cancer (AGC) is the third leading cause of cancer death worldwide \[[@pone.0235848.ref001]\]. Chemotherapy (CT) is capable of improving overall survival (OS) and quality of life for individuals with AGC compared to best supportive care (BSC) \[[@pone.0235848.ref002]\]. In first line, platin-fluoropyrimidine schedules are the most widely recommended option \[[@pone.0235848.ref003]\], whereas the standard of care is the combination of trastuzumab and cisplatin-fluoropyrimidine for tumors that amplify or overexpress human epidermal growth factor receptor-2 (HER2+) \[[@pone.0235848.ref004]\]. The benefit of first-line is limited; up to 25%-30% display progression at their first evaluation of response \[[@pone.0235848.ref005]\] and median progression-free survival (PFS) is 4--7 months \[[@pone.0235848.ref002]\], with approximately 50% of patients in suitable conditions to receive second-line treatment after progression since first-line \[[@pone.0235848.ref006], [@pone.0235848.ref007]\].

Numerous drugs have proven activity in second-line for AGC \[[@pone.0235848.ref008], [@pone.0235848.ref009]\]. Thus, a small randomized trial (NCT00144378) confirmed for the first time that the use of irinotecan vs BSC in second line discreetly prolonged OS \[[@pone.0235848.ref006]\]. In the COUGAR-2 study, docetaxel incremented OS *versus* BSC and likewise demonstrated a benefit in quality of life \[[@pone.0235848.ref010]\]. Both drugs again improved OS compared to BSC in a phase III trial \[[@pone.0235848.ref007]\], while the WJOG-4007 study detected no differences between them or between paclitaxel and irinotecan \[[@pone.0235848.ref009]\]. More recently, the use of ramucirumab plus paclitaxel vs paclitaxel in second line was seen to increase OS in all subgroups in the RAINBOW trial \[[@pone.0235848.ref011]\]. For its part, the REGARD study corroborated a gain in OS with ramucirumab vs BSC \[[@pone.0235848.ref012]\]. Both studies with ramucirumab were bolstered by favorable quality of life analyses, as well as real-world data \[[@pone.0235848.ref013]--[@pone.0235848.ref015]\]. This positions ramucirumab as the recommended second-line strategy, whether in combination or monotherapy \[[@pone.0235848.ref016]\]. There are minimal data concerning how the use of the various alternatives available for second-line treatment has evolved, in addition to their efficacy in actual clinical practice \[[@pone.0235848.ref017]\].

Moreover, pembrolizumab has demonstrated efficacy in a second line study of carcinoma of the esophagus and of the gastroesophageal junction, in the pre-specified subgroup of PDL1-CPS≥10 \[[@pone.0235848.ref018]\], while efficacy in second-line was unproven for advanced gastric or gastro- gastroesophageal junction adenocarcinoma in the KEYNOTE-061 phase III study \[[@pone.0235848.ref019]\]. Treatment in second and successive lines for HER2+ tumors does not currently differ from the rest, given the absence of evidence in favor of anti-HER2 therapy \[[@pone.0235848.ref020], [@pone.0235848.ref021]\]. Nevertheless, these tumors are molecularly dissimilar.

Based on retrospective analysis, certain individuals who do not receive first-line treatment until progression might profit from reintroducing platin-fluoropyrimidine doublets, when the treatment-free interval exceeds three months \[[@pone.0235848.ref022]\]. This subgroup of patients is excluded from most recent second-line clinical trials for AGC \[[@pone.0235848.ref011], [@pone.0235848.ref012]\], and most updated clinical guidelines consider reintroduction of the first-line to be an appropriate alternative \[[@pone.0235848.ref016]\].

Likewise, treatment options with proven efficacy exist in various third-line scenarios \[[@pone.0235848.ref023]--[@pone.0235848.ref025]\]. This availability of options beyond first line makes survival susceptible to the outcomes associated with successive lines of treatment, which could have implications when designing clinical trials. We must therefore revisit the value of intermediate endpoints, such as PFS, as surrogates for OS \[[@pone.0235848.ref026]--[@pone.0235848.ref030]\].

Against this backdrop, we have conducted this study to evaluate patterns of use and outcomes related to each type of strategy in second line and the surrogate function of PFS in an AGC registry (AGAMENON).

Material and methods {#sec006}
====================

Patients and design {#sec007}
-------------------

The patient population assessed derive from the Spanish AGAMENON registry that enlists the collaboration of 34 Spanish hospitals and one center in Chile and recruits consecutive cases of unresectable or metastatic, locally advanced adenocarcinoma of the stomach, gastroesophageal junction, or distal esophagus \[[@pone.0235848.ref031]--[@pone.0235848.ref039]\].

Eligibility criteria are: patients with AGC, aged \>18 years, who received first-line treatment with polyCT routinely administered in clinical practice (two- or three-agent schedule, with or without platin) \[[@pone.0235848.ref040]\], and experienced tumor progression or died during first-line treatment. Those cases that had completed neoadjuvant or adjuvant treatment before 6 months were excluded.

Data are managed through a website (<http://www.agamenonstudy.com/>) consisting of filters and a query-generating system to guarantee reliability and control missing and inconsistent data, as well as errors. Telephone and on-line monitoring (PJF) further guarantee data quality.

Objectives {#sec008}
----------

The primary objective of this study was to describe the pattern of second-line therapies administered from 2008 onward and the associated outcomes. The secondary objective was to assess the correlation between PFS and OS over time, in terms of clinical-pathological variables and use of second lines.

Variables {#sec009}
---------

Post-progression survival (PPS) and PFS-2 were defined as the time between initiation of second-line and all-cause mortality or progression, respectively, censuring those event-free individuals at the time of the last follow up. OS and PFS-1 were defined as the interval between commencement of first-line treatment and death for any cause or progression, respectively, censoring at last follow up.

Second-line strategies were categorized as: (1) platinum-reintroduction, defined as providing a second-line platin-based schedule to individuals who had received platin in first-line with no evidence of progression when plantin was stopped; (2) maintenance of trastuzumab post-progression, consisting of changing the backbone of CT in progression to first-line without discontinuing trastuzumab; (3) regimens containing ramucirumab included use of paclitaxel, irinotecan, or other cytotoxics in combination with ramucirumab; (4) ramucirumab in monotherapy; additionally, patients could receive (5) monoCT or (6) polyCT.

Statistics {#sec010}
----------

Survival functions were Kaplan-Meier estimates. Correlation between PFS and OS was quantified by Kendall's τ associated with Clayton's copula models for bivariate survival data. Sensitivity to second line was evaluated using multivariable binary logistic regression (covariates were HER2 status, histological subtype, signet ring cells, hepatic tumor burden, number of metastatic sites, and interval of time since withdrawal of platin in first-line). Continuous variables were analyzed by means of restricted cubic splines. Treatment effect was appraised using a Cox multivariable proportional hazards model. No data-driven criteria were used for the model specification. The covariates for the multivariable model were chosen by theoretical considerations, as recommended in the literature \[[@pone.0235848.ref041]\]. Thus, ECOG PS (\<2, ≥2), Lauren\'s histopathological subtype (intestinal, diffuse), number of metastatic sites (≤2, \>2), liver tumor burden (≤50, \>50%), HER2 status (negative, positive), PFS-1, and best response to first-line (complete or partial response, stable disease, progressive disease) were used as confounding factors. Restricted cubic splines were used to model the non-linear effect of PFS-1. Given that it is an observational, fixed sample size study, inferences should be interpreted in accordance with the magnitude of the CI with a descriptive purpose (hypothesis generator). Analyses were performed with the R v3.1.6 software package, with rms and Copula.surv libraries \[[@pone.0235848.ref042], [@pone.0235848.ref043]\].

Ethics statement {#sec011}
----------------

This study has Compliance with Ethical Standards. This study was approved in November, 4 th 2014 by the Ethics, Research and Investigation Committee in Hospital Morales Meseguer, Murcia, Spain. The Research Ethics Committee from Morales Meseguer General University Hospital first, and then all the rest of Autonomous Communities and participating hospitals approved the study. The Spanish Agency of Medicines and Medical Devices categorized this study as a post-marketing, prospective follow-up study. In every alive prospective or retrospective registered patient, written informed consent was obtained in order to be included in the study. Participants who were not alive at data collection had previously provided written informed consent to use their medical records for the purposes of research. This was carried out according to the requirements stated in the international guidelines regarding carrying out epidemiological studies and put forth in the International Guidelines for Ethical Review of Epidemiological Studies (Council for the International Organizations of Medical Sciences--CIOMS-, Geneva, 1991), as well as the Declaration of Helsinki (Seoul revision, October, 2008). This document defines the principles that must be scrupulously respected by any and all personas involved in the research. The treatment, communication, and conveyance of the personal data of all participants was adapted to the Organic Law 3/2018, dated December 5, regarding the Protection of Personal Data requiring approval by a Clinical Research Ethics Board (CREB).

Results {#sec012}
=======

Patients and second-line treatments {#sec013}
-----------------------------------

At the time of analysis, 2311 cases had been recorded that met eligibility criteria, 2066 progression events since first-line (89.3%) and 2103 deaths (90.9%). Of the latter, 245 (10.6%) died during first-line. Median PFS-1 was 5.6 months (95% CI, 5.5--5.9), while median OS was 10.2 months (95% CI, 9.8--10.7).

Second-line therapy was given to 1326/2066 (64.1%); 366 (17.7%) received three lines, and 98 (4.7%), four or more. Baseline characteristics are summarized in [Table 1](#pone.0235848.t001){ref-type="table"}. The most common strategies were: monoCT 56.9% (n = 755), polyCT 15.0% (n = 199), ramucirumab+CT 12.6% (n = 167), platinum-reintroduction 8.3% (n = 110), trastuzumab-continuing schedules 6.1% (n = 81), and ramucirumab monotherapy 1.1% (n = 14). [S1 Table](#pone.0235848.s001){ref-type="supplementary-material"} displays characteristics per strategy used.

10.1371/journal.pone.0235848.t001

###### Characteristics at the time of diagnosis.

![](pone.0235848.t001){#pone.0235848.t001g}

  Variables                                                 Total, n (%), n = 2311   Patients receiving 2nd-line, n (%), n = 1326
  --------------------------------------------------------- ------------------------ ----------------------------------------------
  Age, median (range)                                       64 (20--89)              63 (20--86)
  Sex, female                                               672 (29.1)               370 (27.9)
  Lauren subtype                                                                     
      Diffuse                                               745 (32.2)               409 (30.8)
      Intestinal                                            991 (42.8)               589 (44.4)
      Mixed                                                 107 (4.6)                61 (4.6)
      Not Available                                         468 (20.2)               267 (20.1)
  Signet ring cells                                         657 (28.4)               354 (26.7)
  HER2-positive                                             502 (21.7)               318 (23.9)
  ECOG-PS basal                                                                      
      0                                                     533 (23.2)               361 (27.2)
      1                                                     1457 (63.0)              849 (64.0)
      ≥2                                                    321 (12.8)               114 (8.8)
  Tumor stage at diagnosis, locally advanced unresectable   134 (18.1)               74 (5.5)
  Histological grade                                                                 
      *1*                                                   225 (9.7)                152 (11.5)
      *2*                                                   628 (27.2)               361 (27.2)
      *3*                                                   933 (40.4)               525 (39.6)
      *Not available*                                       525 (22.7)               288 (21.7)
  First-line treatment                                                               
      *Anthracycline-based*                                 464 (20.1)               285 (21.5)
      *Cisplatin-based doublet*                             472 (20.4)               302 (22.8)
      *Docetaxel-based*                                     276 (11.9)               154 (11.6)
      *Irinotecan-based*                                    43 (1.9)                 25 (1.9)
      *Oxaliplatin-based*                                   911 (39.4)               498 (37.6)
      *Other*                                               145 (6.3)                62 (4.7)
  Metastases sites                                                                   
      *Ascites*                                             545 (23.6)               289 (21.8)
      *Peritoneal*                                          1011 (43.7)              559 (42.2)
      *Bone*                                                235 (10.2)               112 (8.4)
      *Lung*                                                308 (13.3)               185 (14.0)
      *Liver*                                               876 (37.9)               522 (39.4)
  Burden of liver disease \>50%                             453 (19.6)               247 (18.6)
  Number of metastases \>2                                  629 (27.2)               332 (25.0)
  Primary tumor site                                                                 
      *Esophagus*                                           183 (7.9)                113 (8.5)
      *GEJ*                                                 306 (13.2)               166 (12.5)
      *Stomach*                                             1822 (78.8)              1046 (79.0)
  PFS-1                                                     5.6 (5.4--5.9)           6.8 (6.5--7.1)
  Best response to first-line                                                        
      *Complete response*                                   22 (1.0)                 18 (1.4)
      *Partial response*                                    661 (28.6)               465 (35.1)
      *Stable disease*                                      1028 (44.5)              570 (43.0)
      *Progression disease*                                 600 (26.0)               273 (20.6)

Abbreviations: ECOG-PS, Eastern Cooperative Group Performance Status; GEJ, gastroesophageal junction.

In subjects treated with platinum-reintroduction, the reason for discontinuing platinum in first-line before progression was: having completed the number of cycles established by their center's protocol (71.8%), toxicity (18.2%), patient request (2.7%), and other reasons (7.3%).

Of the participants who received trastuzumab in second-line, 14/81 (17.3%) had not received it in first-line. Trastuzumab was withheld from those 14 patients in first-line because their HER2 status was unavailable (7 cases); due to cardiac comorbidity (n = 3), or oncologist's decision (n = 4). [S2 Table](#pone.0235848.s002){ref-type="supplementary-material"} shows the data of use of these strategies by HER2 status.

[Fig 1](#pone.0235848.g001){ref-type="fig"} illustrates the usage trend of these strategies over time, revealing that the only one with an upward trend is the incorporation of ramucirumab from 2012 onward.

![Time trends in the use of second-line schedules based on HER2 status.\
Abbreviations: polyCT, polychemotherapy; monoCT, monochemotherapy; Ram+CT, ramucirumab+chemotherapy.](pone.0235848.g001){#pone.0235848.g001}

Response rate to second lines {#sec014}
-----------------------------

The response rate to second lines was 12.7% (n = 168); 28.5% had stable disease (n = 378) and the disease control rate (response or stable disease) was 41.2%. Progression occurred in 55.1% (n = 731) and information regarding response was unavailable for 3.7% (n = 49) of the cases. [Fig 2](#pone.0235848.g002){ref-type="fig"} illustrates response rates by second-line strategy and HER2 status. For descriptive purposes, the probability of response to second-line has been represented depending on histopathological subtype, prior response to first-line, HER2 status and platin-free interval ([S1](#pone.0235848.s005){ref-type="supplementary-material"}--[S3](#pone.0235848.s007){ref-type="supplementary-material"} Figs; [S3 Table](#pone.0235848.s003){ref-type="supplementary-material"}). The underlying model suggests differences according to these features. For instance, in diffuse tumors not responding previously to platin, the odds of achieving response to ramucirumab+CT vs monoCT increased as a function of platin-free interval: odds ratio (OR) 1.53 (95% CI, 0.69--3.72) at one month; OR 2.22 (95% CI, 1.30--3.81) at three months, and OR 2.90 (95% CI, 1.41--5.97) at six months. Plots with the probability of response for HER2+ and HER2-negative tumors can be seen in [S2](#pone.0235848.s006){ref-type="supplementary-material"} and [S3](#pone.0235848.s007){ref-type="supplementary-material"} Figs, respectively.

![Response rates according to HER2 and strategy.\
Abbreviations: Pl reint, platinum reintroduction; poly-CT, polychemotherapy; P, paclitaxel; Ram, ramucirumab; CT, chemotherapy; Trastu, trastuzumab; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; NA, not available. \*Paclitaxel was the cytotoxic used in all patients with HER-negative tumors who received ramucirumab+chemotherapy, whereas paclitaxel and other cytotoxics were associated with ramucirumab in HER+ tumors.](pone.0235848.g002){#pone.0235848.g002}

Survival endpoints in second lines {#sec015}
----------------------------------

At the time of analysis, 93.7% had suffered a progression event and 86.2% died after second-line. Median PFS-2 and PPS were 3.1 (95% CI, 2.9--3.3) and 5.8 months (95% CI, 5.5--6.3), respectively. [Fig 3](#pone.0235848.g003){ref-type="fig"} presents survival for both endpoints.

![Survival curves for PFS-2 and PPS (n = 1326).\
Abbreviations: PFS-2, progression-free survival to second-line of treatment; PPS, post-progression survival.](pone.0235848.g003){#pone.0235848.g003}

Survival endpoints for each treatment group are laid out in [Table 2](#pone.0235848.t002){ref-type="table"}. The highest median PFS-2 and PPS were obtained with platinum-reintroduction: 4.2 (95% CI, 3.3--5.0) and 6.7 months (95% CI, 5.5--10.2) and with ramucirumab+CT: 4.1 (95% CI, 3.4--5.2) and 6.5 months (95% CI, 5.5--8.7), respectively. In the case of HER2+ tumors, trastuzumab-containing regimens achieved a median PFS-2 of 4.8 months (95% CI, 3.6--5.7) and PPS of 10.5 months (95% CI, 5.5--12.1). In a sensitivity analysis, after excluding 14 subjects without first-line trastuzumab, the remaining patients obtained a similar median PFS-2/PPS, 4.80 (CI 95%, 3.45--5.75) and 10.8 months (CI 95%, 7.1--14.6) respectively. MonoCT yielded the worst results with median PFS-2 of 2.6 months (95% CI, 2.4--2.7) and PPS of 5.1 months (95% CI, 4.6--5.7). In the multivariable Cox model, taking monoCT as reference, ramucirumab+CT (HR 0.62; 95% CI, 0.51--0.74), platinum-reintroduction (HR 0.76; 95% CI, 0.61--0.94), polyCT (HR 0.81; 95% CI, 0.69--0.96), and trastuzumab+CT (HR 0.58, 95% CI; 0.44--0.77, in HER2+) were associated with better PFS-2. The data as per HER2 subtype are detailed in [Table 2](#pone.0235848.t002){ref-type="table"} and [Fig 4](#pone.0235848.g004){ref-type="fig"}.

![Survival functions since initiation of second-line by HER2 status and treatment strategy.\
Abbreviations: PFS-2, progression-free survival to second-line of treatment; PPS, post-progression survival; CT, chemotherapy; Pacli, paclitaxel.](pone.0235848.g004){#pone.0235848.g004}
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###### Survival endpoints based on the strategy for HER+ and HER-negative tumors.

![](pone.0235848.t002){#pone.0235848.t002g}

  Variables             n/events   Median PFS-2, months (95% CI)   n/events   Median PPS, months (95% CI)
  --------------------- ---------- ------------------------------- ---------- -----------------------------
  **All**                                                                     
  Mono-CT               755/723    2.6 (2.4--2.7)                  755/677    5.1 (4.6--5.7)
  Poly-CT               199/194    3.4 (2.7--3.9)                  199/172    6.3 (5.6--7.2)
  Ram-CT                167/139    4.1 (3.4--5.2)                  167/104    6.5 (5.5--8.7)
  Plat reintroduction   110/104    4.2 (3.3--5.0)                  110/99     6.7 (5.5--10.2)
  **HER2-negative**                                                           
  Ram                   14/11      2.8 (1.8-NA)                    14/10      5.0 (3.0-NA)
  Mono-CT               592/566    2.6 (2.4--2.8)                  592/527    4.9 (4.3--5.4)
  Poly-CT               177/172    3.4 (2.7--4.8)                  177/157    6.2 (5.5--7.1)
  Ram-CT                125/104    3.8 (3.3--5.1)                  125/84     6.5 (5.1--9.4)
  Plat reintroduction   100/95     4.1 (3.2--4.8)                  100/91     6.6 (5.4--9.8)
  **HER2-positive**                                                           
  Mono-CT               163/157    2.7 (2.4--3.2)                  163/150    6.7 (5.2-NA)
  Poly-CT               22/22      3.0 (2.5--5.7)                  22/20      8.6 (5.0--14.9)
  Ram-CT                42/35      4.7 (3.2--6.3)                  42/30      7.3 (5.5--12.1)
  CT + Trastuzumab      81/72      4.8 (3.6--5.7)                  81/66      10.5 (5.5--12.1)
  Plat reintroduction   10/9       5.2 (3.1-NA)                    10/8       11.7 (7.3--13.3)

Abbreviations: Ram, ramucirumab; Plat, platinum; CT, chemotherapy; PFS-2, progression-free survival to second-line of treatment; PPS, post-progression survival.

Correlation of PFS & OS with each treatment strategy {#sec016}
----------------------------------------------------

The correlation between PFS-1 and OS is moderate in the complete series (n = 2311, Kendall's τ  =  0.613), lower in individuals who received a second-line (Kendall's τ  =  0.539). The possibility of having effective second lines available dilutes the surrogate value of PFS-1, principally in individuals who receive CT-ramucirumab. Correlations for each treatment strategy are as follows: ramucirumab+CT (Kendall's τ = 0.413), polyCT (Kendall's τ = 0.503), monoCT (Kendall's τ = 0.539), trastuzumab+CT (Kendall's τ  =  0.566), and platinum-reintroduction (Kendall's τ  =  0.585) ([S4 Table](#pone.0235848.s004){ref-type="supplementary-material"}).

Discussion {#sec017}
==========

Within the context of AGC, second-line therapy has been proven to enhance OS compared to BSC to a statistically significant extent \[[@pone.0235848.ref044]\]. In a meta-analysis of 10 clinical trials, polyCT was more effective than monoCT \[[@pone.0235848.ref045]\], while a network meta-analysis suggests that the combination of paclitaxel+ramucirumab is most likely to be the best schedule available to date \[[@pone.0235848.ref046]\]. However, data with reference to real-world use of second lines (without the usual clinical trial selection biases) are scant. Moreover, there is a paucity of information about the strategies clinicians apply pragmatically, such as platinum-reintroduction or using trastuzumab beyond progression.

To investigate these aspects, we evaluated the use of second-line in the 64.1% of the AGC registry patients who received it, a percentage similar to that observed by other authors \[[@pone.0235848.ref006], [@pone.0235848.ref007]\]. The individuals who received second-line tended to be those who had benefitted most from first-line, with longer PFS-1.

Our data corroborate that polyCT and CT+ramucirumab is superior to monoCT in daily practice \[[@pone.0235848.ref045], [@pone.0235848.ref046]\]. Bearing in mind the safety profile of each strategy in indirect comparisons, and the available scientific evidence, this would endorse the established role of ramucirumab+paclitaxel as the current standard of second-line treatment in AGC. The AGAMENON data endorse this consideration, by revealing a trend toward increased use of ramucirumab, alone and in combination, compared to the remaining second-line strategies, which are declining.

Furthermore, the study indicates that histopathological subtype, therapy administered, time since platin withdrawal, and better response to first-line might be among the factors associated with response. In particular, chemosensitivity to second-line are continuously and non-linearly related to the platin-free period. PFS-1 is a known and consistent predictive factor during second-line therapy \[[@pone.0235848.ref044], [@pone.0235848.ref047]\]. Diffuse tumors are more refractory to second-line treatment than the intestinal subtype, although this depends on the interaction with the platin-free interval. Thus, even in adverse scenarios, such as treatment-resistant diffuse tumors, the probability of response is twofold in those exposed to ramucirumab+CT vs monoCT, indicating that treatment choice is key to achieving benefit.

Based on retrospective analysis, reintroduction of the same drug combination should be contemplated for patients in whom first-line treatment was discontinued and time to progression exceeded three months, provided that any toxicity issues have been resolved \[[@pone.0235848.ref022]\] and as recommended in the most recently updated guidelines \[[@pone.0235848.ref016]\]. In this registry, the reintroduction of firs-line platin-based therapy (10% of Her2- patients) was associated with the highest disease control rate and median PPS. These results are comparable to those of the study by Okines *et al* that revealed that the reintroduction of platin was associated with median PFS-2 and PPS of 3.9 and 6.6 months, respectively \[[@pone.0235848.ref022]\], depending on prior chemosensitivity to platin, platin-free interval, and histological subtype. Therefore, given that platin is sometimes discontinued due to cumulative toxicity, proceeding with fluoropyrimidine until progression \[[@pone.0235848.ref048]\], platin reintroduction might be an especially useful option in intestinal tumors, sensitive to platin in first-line, with a prolonged platin-free interval and in the absence of residual toxicity.

Another strategy arising in this real world evidence analysis is that of using trastuzumab following progression, which in this registry accounts for 25.5% of HER+ tumors, although evidence for trastuzumab in second-line treatment of AGC is lacking \[[@pone.0235848.ref049], [@pone.0235848.ref050]\]. Likewise, our data corroborate the favorable prognostic effect of HER2+ status that is maintained beyond first-line \[[@pone.0235848.ref034]\]. Still, the reader must be mindful of the current lack of positive results in clinical trials that have assessed anti-HER2 therapy in second-line \[[@pone.0235848.ref020], [@pone.0235848.ref021]\], as well as the confirmed benefit of ramucirumab in cases in which trastuzumab was administered in first-line \[[@pone.0235848.ref051]\].

Finally, we have examined the surrogate function of PFS-1 within the context of the availability of treatment strategies after first-line. OS has traditionally been the gold-standard endpoint in clinical trials of first-line therapy for AGC; nonetheless, PFS continues to be routine in various randomized AGC studies \[[@pone.0235848.ref026]--[@pone.0235848.ref028]\]. The advantages of PFS include shortened study duration, smaller sample size, and the absence of interference of post-progression therapies. Overall, the use of intermediate endpoints calls for statistical proof of the validity of the surrogate, as well as the justification of the clinical value that delaying progression has for the patient's quality of life \[[@pone.0235848.ref052]\]. Our data reveal that the correlation between PFS-1 and OS is moderate in actual practice, with a magnitude slightly lower than that reported in the literature \[[@pone.0235848.ref053]\]. In fact, the possibility of having effective second lines available dilutes the surrogate value of PFS-1, principally in individuals who receive CT-ramucirumab. Bearing in mind the gradual increase in the use of ramucirumab in our series, this would call into question the appropriateness of substituting OS for PFS-1 in studies of first line in AGC.

There are several limitations implicit in observational studies, such as this one, in which the criteria that mediate in the decisions regarding second lines depend on the evolution of the disease that are not initially present and, as such, are difficult to capture in a registry of this kind. In addition, patients in this registry received first-line treatment with polyCT, excluding more fragile patients who were only candidates for monoCT. Nevertheless, survival endpoints and baseline characteristics are adequately typified through regular reviews and updating of the information.

Conclusion {#sec018}
==========

In short, our study provides the largest real world practice data set regarding the use of second lines for AGC, backing up the scientific evidence derived from previous clinical trials and smaller retrospective analyses. Our analysis reveals the diversity in second-line treatment for AGC, highlighting the effectiveness of paclitaxel-ramucirumab and, for a selected subgroup of patients, platinum reintroduction; both strategies endorsed by recent clinical guidelines. Additionally, it disputes the role of PFS as a surrogate for OS with the progressive incorporation of more efficacious strategies in successive lines of treatment.
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Dear Dr. Gallego Plazas,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Jul 13 2020 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at <plosone@plos.org>. When you\'re ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled \'Manuscript\'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

We look forward to receiving your revised manuscript.

Kind regards,

Academic Editor

PLOS ONE

Additional Editor Comments:

In general the paper was well-written, a lot of efforts were spent on it. In addition to addressing the reviewers\' concerns, you have to emphasize the main outstanding points of your paper that will catch the readers attention to your paper. Emphasize the points what this retrospective analysis adds or confirms to current knowledge. Consequently you should re-write the conclusion part of the paper since there is no take home points or important findings there. The last para of discussion in unnecessary please delete it (beginning with the readers must..). According to the heterogeneity of the treatment groups cox-regression analysis does not seem to be appropriate unless the including variables are appropriately described for this analysis, since there were lots variables (age, gender, tumor type, performance status, etc). Which model did you use for cox-regression?

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1\. Please ensure that your manuscript meets PLOS ONE\'s style requirements, including those for file naming. The PLOS ONE style templates can be found at

<https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf> and

<https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf>

2\. Please include your tables as part of your main manuscript and remove the individual files. Please note that supplementary tables should remain as separate \"supporting information\" files.

3\. Please provide additional details regarding participant consent.

In the ethics statement in the Methods and online submission information, please ensure that you have specified whether participants who were not alive at data collection had previously provided written informed consent to use their medical records for the purposes of research.

4\. Thank you for including your ethics statement:

\'A multicenter Research Ethics Committee from all the Autonomous Communities and participating hospitals approved the study.\'

\(a\) Please amend your current ethics statement to include the full name of the ethics committee/institutional review board(s) that specifically approved your specific study. 

\(b\) Once you have amended this/these statement(s) in the Methods section of the manuscript, please add the same text to the "Ethics Statement" field of the submission form (via "Edit Submission").

For additional information about PLOS ONE ethical requirements for human subjects research, please refer to <http://journals.plos.org/plosone/s/submission-guidelines#loc-human-subjects-research>.

5\. Thank you for providing the following Funding Statement: 

\"JG Phd. Declares advisory role for Amgen, Bayer, BMS, Ipsen, Lilly, Merck, Roche, Servier. Travel grants from Novartis, Amgen.

None of the funders played any role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.\"

We note that one or more of the authors is affiliated with the funding organization, indicating the funder may have had some role in the design, data collection, analysis or preparation of your manuscript for publication; in other words, the funder played an indirect role through the participation of the co-authors.

a\. If the funding organization did not play a role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript and only provided financial support in the form of authors\' salaries and/or research materials, please review your statements relating to the author contributions, and ensure you have specifically and accurately indicated the role(s) that these authors had in your study in the Author Contributions section of the online submission form. Please make any necessary amendments directly within this section of the online submission form.  Please also update your Funding Statement to include the following statement: "The funder provided support in the form of salaries for authors \[insert relevant initials\], but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the 'author contributions' section."

If the funding organization did have an additional role, please state and explain that role within your Funding Statement.

b\. Please also provide an updated Competing Interests Statement declaring this commercial affiliation along with any other relevant declarations relating to employment, consultancy, patents, products in development, or marketed products, etc. 

Within your Competing Interests Statement, please confirm that this commercial affiliation does not alter your adherence to all PLOS ONE policies on sharing data and materials by including the following statement: \"This does not alter our adherence to  PLOS ONE policies on sharing data and materials." (as detailed online in our guide for authors [http://journals.plos.org/plosone/s/competing-interests](about:blank)) . If this adherence statement is not accurate and  there are restrictions on sharing of data and/or materials, please state these. Please note that we cannot proceed with consideration of your article until this information has been declared.

Please know it is PLOS ONE policy for corresponding authors to declare, on behalf of all authors, all potential competing interests for the purposes of transparency. PLOS defines a competing interest as anything that interferes with, or could reasonably be perceived as interfering with, the full and objective presentation, peer review, editorial decision-making, or publication of research or non-research articles submitted to one of the journals. Competing interests can be financial or non-financial, professional, or personal. Competing interests can arise in relationship to an organization or another person. Please follow this link to our website for more details on competing interests: [http://journals.plos.org/plosone/s/competing-interests](about:blank)

6\. Please amend your manuscript to include your abstract after the title page.

7\. Please upload a copy of Figure 4, to which you refer in your text on page 17. If the figure is no longer to be included as part of the submission please remove all reference to it within the text.

8\. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: [http://journals.plos.org/plosone/s/supporting-information](about:blank)

9\. Your ethics statement must appear in the Methods section of your manuscript. If your ethics statement is written in any section besides the Methods, please move it to the Methods section and delete it from any other section. Please also ensure that your ethics statement is included in your manuscript, as the ethics section of your online submission will not be published alongside your manuscript.

\[Note: HTML markup is below. Please do not edit.\]

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

Reviewer \#2: Partly

\*\*\*\*\*\*\*\*\*\*

2\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: No

\*\*\*\*\*\*\*\*\*\*

3\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: Author describe and comparison the CTs for 2nd line GC patients from real-world data of Spain.

1\. In multivariate analysis for survival, did you include the potential prognostic factor, for example PS, ALP, No of mets and others? As you mentioned, the patients who received mono CT as second line have different condition compared to polyCT.

2\. Do you have a data of the patients who received ICI as 3rd and later line? Because the response of ICI may continue for a long time, the use of ICI may influence the survival of each groups.

3\. In Asian countries, first line platinum agent continue more than 6 courses if the patients have no toxicities and inconvenient. The re-introduction of platinum depends of the strategy of using of first line platinum administration. How the first line platinum are used for the patients with GC in Spain?

Reviewer \#2: Sanchis et al presented a retrospective/observational study on second line treatment options for advanced gastric cancer AGC according to clinical practice in several cancer centers in Spain and Chile. AGC, after first line therapy failure, has poor prognosis but recent developments has added to the clinical practice scenario, new therapeutic approaches with a clear benefit on survival. The addition of VEGFR2 antagonist ramucirumab to taxanes, for instance, increased OS compared to mono-chemotherapy regimens.

The topic addressed by this manuscript is important and the paper is well written, however it lacks novelty and simply provide a description of several regimens used in second-line setting throughout the last 12 years. It appears clear that the use of ramicurumab is climbing in the most recent time due to the wide spreading of this agents from 2015 when RAINBOW trial was published. Moreover, the methods appear to be sound but the correlation of PFS and OS with each treatment strategy in the results section is not easily readable and should be expanded and better performed to ensure that readers understand exactly what the researchers wanted to state. Thirdly, platinum re-introduction, when feasible, could be a valid therapeutic option, however the conclusion of the manuscript appears to be way stronger due to low number (8.3%), the paucity of patients that will be able to tolerate the reintroduction of platinum-doublet in this setting and the results, totally comparable to Ram-taxane, which shows a better toxicity profile.

Lastly, the dissertation on PFS as adequate surrogate of OS is interesting. This is a current unmet need in oncology research. Specifically, in this study, authors focused on PPS (post progression survival). According to their data, it that could have some relevance in Her2 positive AGC since the anti-her2 action of trastuzumab, even though a radiologic progression, keeps the ability to control the Her-2 enriched population which could lead to a longer overall survival. However, for Her2-negative tumors, the magnitude of the benefit is lower, reaching less than 3 months in the best subgroup. In this case, QoL has much more impact and relevance for patients and should be primarily assessed in studies on poor prognosis cancer after first setting

\*\*\*\*\*\*\*\*\*\*

6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: Yes: Ken Kato

Reviewer \#2: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at <figures@plos.org>. Please note that Supporting Information files do not need this step.
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Author response to Decision Letter 0

20 Jun 2020

Dear editor,

In accordance with the Editor's suggestions and concerns regarding the manuscript entitled, "Second-line treatment in advanced gastric cancer: data from the Spanish AGAMENON registry", please find the new version enclosed.

On behalf of all the co-authors, I would like to thank the editor and the reviewers for their thoughtful and insightful comments on our work, which we have considered very closely, while preparing this revised version of the manuscript as detailed in the point-by-point reply named Response to Reviewers.

We trust that we have addressed all the issues raised by the reviewers to their satisfaction and you now find the manuscript suitable for publication in your journal.

Thank-you very much for your consideration.

Respectfully,

MD PhD, Javier Gallego Plazas

###### 

Submitted filename: Response to reviewers.docx

###### 

Click here for additional data file.
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PONE-D-20-09864R1

Dear Dr. Gallego Plazas,

We're pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you'll receive an e-mail detailing the required amendments. When these have been addressed, you'll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at <http://www.editorialmanager.com/pone/>, click the \'Update My Information\' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at <authorbilling@plos.org>.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they'll be preparing press materials, please inform our press team as soon as possible \-- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <onepress@plos.org>.

Kind regards,

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers\' comments:

10.1371/journal.pone.0235848.r004
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Second-line treatment in advanced gastric cancer: data from the Spanish AGAMENON registry

Dear Dr. Gallego:

I\'m pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they\'ll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact <onepress@plos.org>.

If we can help with anything else, please email us at <plosone@plos.org>.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Hakan Buyukhatipoglu

Academic Editor

PLOS ONE

[^1]: **Competing Interests:**Dr. Javier Gallego declares advisory role for Amgen, Bayer, BMS, Ipsen, Lilly, Merck, Roche, Servier, and travel grants from Novartis, Amgen. No other authors have competing interests to declare. This does not alter our adherence to PLOS ONE policies on sharing data and materials.
